X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NOVARTIS - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NOVARTIS IPCA LABS/
NOVARTIS
 
P/E (TTM) x 29.7 398.8 7.4% View Chart
P/BV x 4.4 31.9 13.7% View Chart
Dividend Yield % 0.1 1.4 7.5%  

Financials

 IPCA LABS   NOVARTIS
EQUITY SHARE DATA
    IPCA LABS
Mar-18
NOVARTIS
Mar-18
IPCA LABS/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs695758 91.7%   
Low Rs400579 69.1%   
Sales per share (Unadj.) Rs260.2228.4 113.9%  
Earnings per share (Unadj.) Rs19.031.7 59.8%  
Cash flow per share (Unadj.) Rs33.132.8 100.9%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.5 12.2%  
Book value per share (Unadj.) Rs213.0297.1 71.7%  
Shares outstanding (eoy) m126.2024.69 511.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.9 71.9%   
Avg P/E ratio x28.921.1 137.1%  
P/CF ratio (eoy) x16.620.4 81.2%  
Price / Book Value ratio x2.62.2 114.3%  
Dividend payout %5.331.5 16.7%   
Avg Mkt Cap Rs m69,12016,505 418.8%   
No. of employees `00013.30.7 1,984.1%   
Total wages/salary Rs m7,3591,445 509.2%   
Avg. sales/employee Rs Th2,477.48,441.3 29.3%   
Avg. wages/employee Rs Th555.22,163.6 25.7%   
Avg. net profit/employee Rs Th180.61,173.1 15.4%   
INCOME DATA
Net Sales Rs m32,8365,639 582.3%  
Other income Rs m4181,718 24.3%   
Total revenues Rs m33,2547,357 452.0%   
Gross profit Rs m4,505-63 -7,207.7%  
Depreciation Rs m1,77725 7,024.9%   
Interest Rs m24055 434.4%   
Profit before tax Rs m2,9051,575 184.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511792 64.6%   
Profit after tax Rs m2,394784 305.5%  
Gross profit margin %13.7-1.1 -1,237.8%  
Effective tax rate %17.650.3 35.0%   
Net profit margin %7.313.9 52.5%  
BALANCE SHEET DATA
Current assets Rs m19,4559,522 204.3%   
Current liabilities Rs m10,0763,296 305.7%   
Net working cap to sales %28.6110.4 25.9%  
Current ratio x1.92.9 66.8%  
Inventory Days Days9837 267.4%  
Debtors Days Days6728 235.5%  
Net fixed assets Rs m20,26046 44,042.6%   
Share capital Rs m252123 204.5%   
"Free" reserves Rs m26,6337,213 369.2%   
Net worth Rs m26,8867,336 366.5%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17311,105 370.8%  
Interest coverage x13.129.5 44.4%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.5 157.1%   
Return on assets %6.47.6 84.7%  
Return on equity %8.910.7 83.4%  
Return on capital %10.822.2 48.4%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64261 25,812.0%   
Fx outflow Rs m4,8843,630 134.5%   
Net fx Rs m10,759-3,570 -301.4%   
CASH FLOW
From Operations Rs m3,4111,610 211.9%  
From Investments Rs m-1,354687 -197.1%  
From Financial Activity Rs m-1,304-2,677 48.7%  
Net Cashflow Rs m753-380 -198.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 2.0 570.0%  
FIIs % 25.3 1.6 1,581.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.5 80.9%  
Shareholders   36,892 41,647 88.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 24, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS